Jiangsu Wuzhong Pharmaceutical Group Corporation announced a equity round of funding for gross proceeds of CNY 340 million with existing investor JiangSu WuZhong Pharmaceutical Development Co., Ltd. on January 5, 2022. As a part of the round, the registered capital of the company will increase from CNY 400 million to CNY 740 million. Post the capital increase, the investor will retain its 100% stake in the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.94 CNY | -0.55% | -3.78% | +33.09% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+33.09% | 1.07B | |
+32.04% | 694B | |
+29.39% | 593B | |
-1.48% | 371B | |
+19.99% | 331B | |
+7.27% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.38% | 169B |
- Stock Market
- Equities
- 600200 Stock
- News JiangSu WuZhong Pharmaceutical Development Co., Ltd.
- Jiangsu Wuzhong Pharmaceutical Group Corporation announced that it expects to receive CNY 340 million in funding from JiangSu WuZhong Pharmaceutical Development Co., Ltd.